Tg Therapeutics, Inc.

Get Full Access

Description

  • TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs to develop IRAK4 inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City and is traded on NASDAQ under the ticker symbol TGTX.
  • location

    Headquarters:2 Gansevoort Street , New York, New York, United States

    More
  • Tg Therapeutics, Inc. phone

    Phone Number: +1 212-554-4484

  • Tg Therapeutics, Inc. website

    Website: https://www.tgtherapeutics.com

  • Tg Therapeutics, Inc. employees

    Employees:189

  • Tg Therapeutics, Inc. revenue

    Revenue:$100 - 250M

  • Tg Therapeutics, Inc. legal name

    Legal Name:Tg Therapeutics, Inc.

  • Tg Therapeutics, Inc.'s Social Media

    Tg Therapeutics, Inc. linkedin Tg Therapeutics, Inc. twitter
  • done Is this data correct?
  • |  NAICS Code: 511210  |

    Show More
Person level website identification

Chief Operating Officer for Tg Therapeutics, Inc.

Peter Sportelli

Chief Operating Officer

Person level website visitor identification

Sell more in less time!

Buyer intent data, anonymous visitor identification, first party data integration backed by a massive contact database that will supercharge your sales team. Schedule a demo to learn more!

View Employees

Peter Sportelli

Chief Operating Officer

Adam Waldman

Chief Commercial Officer

Jill Myers

Vice President Biologics Cmc

Anne Frederick

Vice President, Regulatory Affairs

Lesa Gardner

Vice President Clinical Affairs

Frequently Asked Questions regarding Tg Therapeutics, Inc.

  • Where are Tg Therapeutics, Inc.'s Headquarters?

    Tg Therapeutics, Inc.'s Headquarters are in 2 Gansevoort Street ,New York,New York,United States

  • What is Tg Therapeutics, Inc.'s phone number?

    Tg Therapeutics, Inc.'s phone number is +1 212-554-4484

  • What is Tg Therapeutics, Inc.'s official website?

    Tg Therapeutics, Inc.'s official website is https://www.tgtherapeutics.com

  • What is Tg Therapeutics, Inc.'s Revenue?

    Tg Therapeutics, Inc.'s revenue is $100 - 250M

  • What is Tg Therapeutics, Inc.'s NAICS code?

    Tg Therapeutics, Inc.'s NAICS code is 511210

  • How many employees are working in Tg Therapeutics, Inc.

    Tg Therapeutics, Inc. has 189 employees

  • What is Tg Therapeutics, Inc.'s Industry?

    Tg Therapeutics, Inc. is in the industry of Biotechnology

  • Who is Tg Therapeutics, Inc.'s Chief Operating Officer?

    Tg Therapeutics, Inc.'s Chief Operating Officer is Peter Sportelli

Company Directory